This is consistent with the fact that IL-1β–neutralizing treatment is effective in some but not all MKD patients (56, 63, 64), and therapies targeting IL-6 and TNF-α can also be beneficial (64). This evidence concerns the gene IL1B and mevalonic aciduria.